A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Melanoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Has histologically or cytologically confirmed melanoma. 2. Has unresectable Stage Ill or Stage IV melanoma. 3. Has the presence of at least 1 measurable ┬Ělesion by CT or MRI

You may not be eligible for this study if the following are true:

  • 1. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy. 2. Has a known additional malignancy that is progressing or requires active treatment within the past 2 years. 3. Has known active CNS metastases and/or carcinomatous meningitis.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.